1,728 reports of this reaction
2.2% of all LIRAGLUTIDE reports
#9 most reported adverse reaction
OFF LABEL USE is the #9 most commonly reported adverse reaction for LIRAGLUTIDE, manufactured by Novo Nordisk. There are 1,728 FDA adverse event reports linking LIRAGLUTIDE to OFF LABEL USE. This represents approximately 2.2% of all 79,181 adverse event reports for this drug.
Patients taking LIRAGLUTIDE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for LIRAGLUTIDE, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for LIRAGLUTIDE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 1,728 FDA reports for LIRAGLUTIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 2.2% of all adverse event reports for LIRAGLUTIDE, making it a notable side effect.
If you experience off label use while taking LIRAGLUTIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.